Literature DB >> 33915157

Recent progress on targeting ferroptosis for cancer therapy.

Guangxiang Xu1, Han Wang2, Xiaoling Li3, Riming Huang4, Lianxiang Luo5.   

Abstract

Ferroptosis is a new mode of cell death different from cell necrosis, autophagy, apoptosis, and pyroptosis, which depends on the accumulation of reactive oxygen species (ROS) caused by iron-mediated lipid peroxidation, exhibits cellular, molecular, and gene-level characteristics distinct from other cell deaths. Since ferroptosis discovery, it has become a new target for antitumor therapy actively explored by researchers. In this review, we provide an overview of the known mechanisms that regulate the sensitivity of cancer cells to ferroptosis and the research progress of ferroptosis-related drugs (western medicine, traditional Chinese medicine, and nanomedicine), as well as the relationship between ferroptosis and cancer treatment, tumor drug resistance, and antitumor immunotherapy.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer therapy; Drug resistance; Ferroptosis inducers; Ferroptosis inhibitors; Ferroptosis regulation; Immunotherapy

Year:  2021        PMID: 33915157     DOI: 10.1016/j.bcp.2021.114584

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

1.  Establishment and Validation of a Ferroptosis-Related lncRNA Signature for Prognosis Prediction in Lower-Grade Glioma.

Authors:  Qian-Rong Huang; Jian-Wen Li; Ping Yan; Qian Jiang; Fang-Zhou Guo; Yin-Nong Zhao; Li-Gen Mo
Journal:  Front Neurol       Date:  2022-06-27       Impact factor: 4.086

2.  SIRT6 promotes ferroptosis and attenuates glycolysis in pancreatic cancer through regulation of the NF-κB pathway.

Authors:  Shuangxi Gong; Lixin Xiong; Zhen Luo; Qinghua Yin; Ming Huang; Yang Zhou; Jian Li
Journal:  Exp Ther Med       Date:  2022-06-08       Impact factor: 2.751

3.  LncRNA PELATON, a Ferroptosis Suppressor and Prognositic Signature for GBM.

Authors:  Haijuan Fu; Zhaoyu Zhang; Danyang Li; Qingqing Lv; Simin Chen; Zuping Zhang; Minghua Wu
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

Review 4.  Ferroptosis-Inducing Nanomedicine for Cancer Therapy.

Authors:  Yang Wang; Tianfu Liu; Xiang Li; Hui Sheng; Xiaowen Ma; Liang Hao
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

5.  Identification of the ferroptosis-related long non-coding RNAs signature to improve the prognosis prediction and immunotherapy response in patients with NSCLC.

Authors:  Meng Li; Yanpeng Zhang; Meng Fan; Hui Ren; Mingwei Chen; Puyu Shi
Journal:  BMC Med Genomics       Date:  2021-12-03       Impact factor: 3.063

Review 6.  Targeting ferroptosis-based cancer therapy using nanomaterials: strategies and applications.

Authors:  Lianxiang Luo; Han Wang; Wen Tian; Xiaoling Li; Zheng Zhu; Riming Huang; Hui Luo
Journal:  Theranostics       Date:  2021-10-22       Impact factor: 11.556

Review 7.  Ferroptosis: The Silver Lining of Cancer Therapy.

Authors:  Zhengming Tang; Zhijie Huang; Yisheng Huang; Yuanxin Chen; Mingshu Huang; Hongyu Liu; Q Adam Ye; Jianjiang Zhao; Bo Jia
Journal:  Front Cell Dev Biol       Date:  2021-11-29

8.  Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer.

Authors:  Wenqing Tang; Fangshi Xu; Meng Zhao; Shuqun Zhang
Journal:  BMC Cancer       Date:  2021-10-29       Impact factor: 4.430

9.  Systematic Analysis and Validation of the Prognosis, Immunological Role and Biology Function of the Ferroptosis-Related lncRNA GSEC/miRNA-101-3p/CISD1 Axis in Lung Adenocarcinoma.

Authors:  Xiulin Jiang; Yixiao Yuan; Lin Tang; Juan Wang; Dahang Zhang; Lincan Duan
Journal:  Front Mol Biosci       Date:  2022-03-07

10.  Epstein-Barr virus latency programs dynamically sensitize B cells to ferroptosis.

Authors:  Eric M Burton; Jewel Voyer; Benjamin E Gewurz
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-11       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.